多发性硬化患者血清TGF-β_1及sICAM-1水平测定  

Determining Soluble Intercellular Adhesion Molecule-1 and Transforming Growth Factor-β_1 in Serum from Multiple Sclerosis

作　　者：何志义[1] 吕昌龙[1] 刘风芝[1] 王钢[1] 付国[1] 

机构地区：[1]中国医科大学,沈阳110001

出　　处：《中国医科大学学报》1999年第5期355-356,363,共3页Journal of China Medical University

摘　　要：目的：探讨可溶性细胞间粘附分子（ｓＩＣＡＭ－１）和转化生长因子－β１（ＴＧＦ－β１ ）在多发性硬化（ＭＳ）发生、发展中的作用。方法：采用ＥＬＩＳＡ方法，测定了３０ 例ＭＳ患者血清中ｓＩＣＡＭ－１ 和ＴＧＦ－β１ 的水平。结果：与对照组和ＮＩＮＤ组相比，ＭＳ患者血清ＴＧＦ－β１ 水平明显下降（Ｐ＜ ０．０１），而ｓＩＣＡＭ－１ 水平则明显升高（Ｐ＜ ０．０１）。动态观察显示，随着病情的好转，ＴＧＦ－β１ 水平逐渐升高，而ｓＩＣＡＭ－１ 水平则逐渐下降。ＭＳ患者头ＭＲＩ上病灶越大，ｓＩＣＡＭ－１ 水平升高也越明显。结论：血清ＴＧＦ－β１Objective: We were to explore the effects of soluble intercellular adhesion molecule 1 (sICAM 1) and transforming growth factor β 1 (TGF β 1) on the development of multiple sclerosis (MS). Methods: Levels of sICAM 1 and TGF β 1 in serum were measured in 30 patients with MS by ELISA method. Results: The level of TGF β 1 decreased, and the level of sICAM 1 increased significantly in the serum of MS, as compared with those in normal and non inflammatory neurologic disease (NIND) groups (P<0.01). The level of sICAM 1 decreased, and the TGF β 1 levels increased after treatment of MS. The larger the sizes of foci in MRI were, the more obviously, the level of sICAM 1 increased. Conclusion: Measuring serum sICAM 1 and TGF β 1 might be important parameters for clinical evaluation in patients with MS.

关 键 词：多发性硬化 TGF-Β1 SICAM-1 测定 

分 类 号：R744.51[医药卫生—神经病学与精神病学]